WO2017200418A1

WO2017200418A1 - Use of (1s,3ar,4r,7as)-n-(2,2,4,7a-tetramethyloctahydro-1,4-ethanoindene-3a-yl)-acetamide as an inhibitor of influenza virus reproduction

Info

Publication number: WO2017200418A1
Application number: PCT/RU2017/000281
Authority: WO
Inventors: Ольга Ивановна ЯРОВАЯ; Анна Андреевна ШТРО; Яна Рафаэлевна ОРШАНСКАЯ; Владимир Викторович ЗАРУБАЕВ; Вениамин Абрамович ХАЗАНОВ; Нариман Фаридович САЛАХУТДИНОВ
Original assignee: Общество С Ограниченной Ответственностью "Дакор"
Priority date: 2016-05-16
Filing date: 2017-05-02
Publication date: 2017-11-23
Also published as: RU2616255C1

Abstract

The invention relates to the field of medicine and concerns a (1S,3aR,4R,7aS)-N-(2,2,4,7a-tetramethyloctahydro-1,4-ethanoindene-3a-yl)-acetamide compound of formula I, including spatial isomers thereof, including optically active forms. Proposed is the use of the indicated compound as an inhibitor of influenza virus reproduction. Technical result: the compound of formula I inhibits the replication of rimantidine-resistant A/California/07/09 (H1N1)pdm09 and A/Puerto Rico/8/34 (H1N1) influenza virus; the chemotherapeutic index of the compound significantly exceeds that of comparator drugs; the compound provides improved suppression of influenza virus replication and broadens the range of influenza virus reproduction inhibitors available to overcome drug resistance in modern viral strains.

Description

APPLICATION (18, Za, 4K, 7a8) - ^ (2,2,4,7a-TETRAMETHYL-HYDRO-1,4-ETHANOINDEN-ZA-IL) -ATSETAMIDE AS AN INHIBITOR

REPRODUCTION OF VIRUS INFLUENZA

FIELD OF THE INVENTION

The invention relates to chemistry and medicine, namely to medicines, in particular, to the known compound (l S, 3aR, 4R, 7aS) -N- (2,2,4,7- tetramethyl octahydro-1, 4-ethanoinden-Za- il) -acetamide of the formula I (including its spatial isomes, including optically active forms):

in which the biological activity of inhibiting the reproduction of the influenza virus has been identified.

State of the art

Influenza is an acute infectious disease of the respiratory tract caused by an RNA-containing virus of high epidemiological and clinical significance with a high incidence of complications among high-risk individuals.

Influenza viruses and other acute respiratory viral infections (SARS) cause massive outbreaks of disease, which take on an epidemic almost every year. From 27 to 41 million cases of these diseases are registered annually, in particular, from 5 to 15% of the Russian population is ill with the flu annually. Influenza and SARS remain virtually uncontrolled diseases due to the high variability of the antigenic structure of circulating influenza viruses and the heterogeneity of the SARS pathogens. In addition, influenza viruses and other acute respiratory viral infections are able to change their properties and pathogenicity. The latest example of such changes is the HlNlpdm09 influenza pathogen that circulates in the 2009–2010 epidemic season. It is called “swine flu,” the same strain of the virus caused an epidemic in the 2015–2016 season.

Antiviral agents for treating influenza are an extremely limited group of drugs, and most of them are known to have resistance to viruses. The creation of antiviral drugs is the immediate prospect of the development of medical science in the field of the development of means for the treatment and prevention of viral infections [Eropkin M.Yu., Zarubaev V.V. The current state of development of new antiviral drugs against influenza and SARS // Pharmaceutical Bulletin. - 2012. N2I. - C 68]. Due to the features of the genome organization (lack of a mechanism for correcting replication errors) and the short life cycle, the influenza virus has a high mutation rate. As a result, the antigenic structure of the virus is highly susceptible to changes as a result of the selective pressure of the host’s immune system. In addition, the use of chemotherapy is perceived by the virus as a selection factor, as a result of which the formation of resistant strains also occurs. These two processes lead to the appearance of variants of viruses that can avoid both the activity of neutralizing antibodies, and thereby escape from the body's immune response, and overcome the effect of chemotherapy drugs aimed at a certain stage of virus reproduction. Moreover, each type of virus has its own mechanism of adaptation to a chemical preparation [Ison MG Antivirals and resistance: influenza virus // Current Opinion in Virology - 201 1, - V 1. P. 563-573].

Known neuraminidase inhibitors registered in Russia:

Oseltamivir (Tamiflu) and Zanamivir (Relenza), as well as those used in the USA: Peramivir (Rapiakta) and Laninamivir (Inavir), which act at the stage of budding newly synthesized influenza virions from the cell membrane, blocking the cleavage of particles of viral offspring from the cell surface [Ison M.G. Clinical use of approved influenza antivirals: therapy and prophylaxis. // Influenza Other Respi Viruses. 2013; 7 Suppl 1: 7-13]. In addition, viral neuraminidase inhibitors prevent the virions from accessing target cells by blocking the neuraminidase cleavage of mucopolysaccharides of the mucus of the upper respiratory tract. The practice of using neuraminidase inhibitors in the treatment of influenza has shown that the high effectiveness of this group of drugs is limited by the early stage of the disease.

Anti-influenza drugs of a different mechanism of action are also known, for example, the drug Remantadine (α-methyl-1-adamantylmethylamine hydrochloride) and Amantadine (1-aminoadamantane) [Davies, WL; Grunert, RR; Haff, RF; McGahen, JW; Neumayer, EM; Paulshock, M .; Watts, JC; Wood, TR; Hermann, EC; Hoffmann, CE Antiviral Activity of 1 - Adamantanamine (Amantadine) // Science. - 1964. - V. 144. P. 862]. These compounds block the influenza virus M2 protein, thereby inhibiting the process of hemagglutinin cleavage, fusion of the virus and lysosomal vacuole membranes and the virus “undressing process” [Scholtissek C, Quack G., Klenk HD, Webster RG // Antiviral Res. 1998, V. 37, P. 83-95]. The mechanism of action of these drugs has been studied quite fully [Cady SD, Schmidt-Rohr K., Wang J., Soto CS, DeGrado WF, Hong MH Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers // Nature. 2010. Vol. 463. P. 689-692]. Adamantane preparations are significantly cheaper and easier to manufacture than commercially available neuraminidase inhibitors, which makes them more affordable for the treatment and prevention of influenza in the population. However, currently, as a result of the widespread use of adamantane preparations, their antiviral properties against influenza A viruses have been significantly lost. However, scaffolds remain attractive as the basis for the design of antiviral drugs. So, it is known a tool based on deutiforin (2- (G-aminoethyl) bicyclo [2.2.1] heptane, which is one of the most interesting drugs based on natural bicyclic framework compounds - bornanes [Patent RU 2448692 C2, op. 27.04.2012].

The closest prototype to the claimed compound is remantadine, which is methyl tricyclo hydrochloride [3.3.1.1 /. 7 decane-1-methanamine of formula II.

A disadvantage of the known compound is its low antiviral activity, caused by the resistance of the vast majority of influenza strains to this drug.

SUMMARY OF THE INVENTION

The objective of the invention is to identify a new effective inhibitor of reproduction of influenza virus, which can be synthesized from available reagents.

Effect: increasing the efficiency of suppressing reproduction of the influenza virus and expanding the range of inhibitors of reproduction of the influenza virus to overcome the drug resistance of modern viral strains.

The problem is solved by the use of the known compound, which is (18, ZaK, 4, 7a8) - - (2,2,4,7a-tetramethyl octahydro-1, 4-ethanoinden-Za-yl) -acetamide I (including its spatial isomers, including optically active forms):

t

which revealed a new biological activity, consisting in the inhibitory effect on the reproduction of influenza virus.

Compound I is described in [O. I. Yarovaya, D.V. Korchagina, T.V. Rybalova, Yu.V. Gatilov, M.P. Half, V.A. Barkhash. Interaction of karyofillen, isocariophilen and their epoxy derivatives with acetonitrile under the conditions of the Ritter reaction \\ ZhOKh 2004, 40, 1 1, 1641 -1646].

The proposed compound can be obtained as follows:

Isocariophyllene is used as the starting material for the synthesis of the target compound I. It was shown that the dissolution of isocariophilen in the acetonitrile-sulfuric acid system, followed by treatment with an aqueous solution of sodium carbonate, leads to the formation of the optically active compound (I) as the main product. The structure of the obtained compound was established by x-ray diffraction analysis. The reaction proceeds with a fairly good yield, the isolation of the target compound I occurs by crystallization from a solvent, it is sufficient to wash with hexane to purify the target compound.

isocariophilen

Isocariophyllene, a natural sesquiterpenoid found in many essential oils and larch bark, is a stable cis isomer of karyofillen, the more common sesquiterpenic hydrocarbon in nature. Karyofillen is found in many essential oils: buds and stems of cloves, copaib balsam. Ceylon cinnamon, West Indian sandalwood, catnip (14%), as well as lavender, thyme, pepper, pimento. Karyofillen is obtained as a by-product of the separation of eugenol from clove oil, and isocaryophyllene is obtained by isomerization of caryophyllene. The backbone of compound I coincides with the backbone of the natural ginsenol alcohol isolated from Panax ginseng ginseng root (Iwabuchi, H.; Yoshikura, M .; Kamisako, W. Studies on the sesquiterpenoids of Panax ginseng CA Meyer. II. Isolation and structure determination of insenol, a novel sesquiterpene alcohol Chem. Pharm. Bull. 1988, 36, 2447).

Glnsenol

Studies of the biological activity of compound I in relation to the influenza virus have shown the extremely high effectiveness of this substance as an inhibitor of the reproduction of this virus.

The obtained quantitative indicators of inhibition confirm the high activity in suppressing the replication of influenza virus in the MDCK cell culture by compound I, which is 120 times or more higher than that of the reference standards amantadine and remantadine. The use of adamantane derivatives as comparison preparations is due to the similarity of structures: the presence of frame structural fragments in both compound I and comparison standards.

For compound I, an in vivo toxicity study was performed. It has been shown that

The LD50 of compound I exceeds 5000 mg / kg body weight, which confirms the low toxicity of these compounds.

The invention is illustrated by the following examples:

Example 1. Preparation of 1, 7,7-trimethylbicyclo [2.2.1] heptan-2-ylidene-aminoethanol.

The conversion of isocaryophylline in the acetonitrile-sulfuric acid system. To a solution of 0.5 g of isocariophyllene in 10 ml of acetonitrile, 0.2 ml of sulfuric acid was added with stirring, stirred for 5 min, the reaction mixture was neutralized with a saturated solution of Na ₂ C0 ₃ . White needle crystals of compound (I) precipitate from the organic layer upon standing (mp 213-214 ° С). The reaction product was filtered, washed with hexane, the mass of the crystallized compound (I) 0.38 g, the mass of the organic extract containing, according to GC / MS, 71% amide (I) - 0.18 g.

(15, ZaK, 4K, 7a5) -K- (2,2,4,7a-tetramethyl octahydro-1, 4-ethanoinden-Za-yl) - acetamide (I). NM spectrum? 1 ⁿ (δ, ppm, J, Hz): 0.80 s (С 12НЗ), 1.03 s and 1.19 s (С 13НЗ, С14НЗ), 1.10 s (С15НЗ), 1.12 m (NI), 1.24-1.35 m (2H, H2, H9), 1.37 dd (H4, J4.3'3.5, J4.3 2.5), 1.41-1.64 m (4H, HI, NZ, NI ', Η2'), 1.75-1.93 m (ZN, ΗΙ Ο ', N9 ^* , NZ'), 1.94 s (S18NZ), 2.28 d and 2.36 d (2H6, J6.6'15) - system AB, 5.45 bs (HI 6). 13C NMR spectrum (δ ppm): 40.15 s (C1), 33.62 t (C2), 25.86 t (C3), 56.08 d (C4), 36.41 s (C5), 45.05 t (C6), 68.07 s (C7), 45.83 s (C8), 33.68 t (C9), 21.43 t (C Yu), 34.88 t (CI 1), 26.85 k (C 12), 28.16 k and 34.07 k (C13, C14), 30.52 k (C15), 169.48 s (C17), 24.26 k (C18). Elemental composition. Found, m / z: 263.22516 [M] +. C17H29NO. Calculated: 263.22490. IR spectrum v (CC14, cm -1): 1670.1 (C = 0), 3440.8 (NH).

Example 2. The study of the toxicity of the claimed compound I.

The toxicity of the agents has been studied for MDC cells. MDCK cells were seeded in 96-well plates and cultured at 37 ° C in MEM medium supplemented with 10% cattle serum in an atmosphere of 5% CO2 (in a Sanyo-175 gas flow incubator) to a monolayer state. A stock solution of a concentration of 10 mg / ml in dimethyl sulfoxide was prepared from the test compound, after which a series of twofold dilutions of the preparations in MEM medium from 1000 to 3.75 mg / ml was prepared. The dissolved preparation was added to the wells of the plates and incubated for 2 days at 37 ° C. At the end of this period, the cells were washed 2 times for 5 minutes with phosphate-buffered saline, and the number of living cells was estimated using a microtetrazolium test (MTT). For this purpose, 100 μl of a solution (5 mg / ml) of 3- (4,5-dimethylthiazolyl-2) 2,5-diphenyltetrazolium bromide (ICN Biochemicals Inc., Aurora, Ohio) in physiological saline was added to the wells of the plates. Cells were incubated at 37 ° C in an atmosphere of 5% CO2 for 2 hours and washed 5 minutes with phosphate-buffered saline. The precipitate was dissolved in 100 μl per well of DMSO, after which the absorbance in the wells of the plates was measured on a Victor 1420 multifunction reader (Perkin Elmer, Finland) at a wavelength of 535 nm. According to the test results, a 50% cytotoxic dose (CTD50) was determined for each product, i.e. the concentration of the compound that causes the death of 50% of the cells in the culture. The results are shown in the table.

Example 3. The study of the antiviral activity of drugs on two types of viruses.

Determination of antiviral activity of the drug was performed on cells

MDCK in 96 well cell culture plates. The compound was dissolved in a supporting medium for cells, introduced into the wells of the panels with a cell monolayer and incubated for 1 hour at 36 ° C in an atmosphere of 5% CO2.

From a virus-containing fluid (strains A / Califprnia / 07/09 (HlN l) pdm09 and A / Puerto Rico / 8/34 (H1N1)) a series of ten-fold dilutions from 10-1 to 10-7 were prepared added to the wells with the preparations and incubated at 36 ° C for 48 hours in an atmosphere of 5% CO2. At the end of the incubation period, 100 μl of culture fluid was mixed with an equal volume of 1% chicken red blood cells in separate round-bottom plates. Analysis was carried out after 60 minutes of incubation at 20 ° C. For the titer of the virus, the reciprocal of the decimal logarithm of the highest dilution of the original virus, capable of inducing a positive hemagglutination reaction in the well, was taken and expressed in the amount of 50% of infectious doses (ID50). Virus-inhibitory effect of the studied compounds was evaluated by reducing the titer of the virus in the experiment compared with the control. Based on the data obtained, a 50% inhibitory dose of ED50 was calculated, that is, the concentration of the drug that halves the level of viral replication (by 0.3 log ID50), and the chemotherapeutic index, or selectivity index (SI), which is the ratio of CTD50 to ED50.

In the study of the inhibition of reproduction of influenza virus by compound I and reference standards (amantadine, remantadine and deuteriforin), the results are shown in the table.

Table.

The table shows that compound I exhibits a pronounced antiviral activity along with low toxicity. The chemotherapeutic index of compound I significantly exceeds that of comparison drugs. An advantage of this compound is its activity against the rimantadine-resistant strain of influenza virus A / California / 07/09 (HlNl) pdm09. which indicates the prospects its use for the treatment of modern epidemiologically relevant viruses, the vast majority of which are resistant to remantadine.

Example 4

Studies of acute toxicity of the compound were performed on outbred mice of runoff CD-I SPF status. The test substance in doses of 5000 mg / kg (6 mice), 1000 mg / kg (6 mice), 500 mg / kg (6 mice) was administered in a volume of 1 ml intragastrically once in suspension, the carrier was an aqueous 0.5% solution of carboxymethyl cellulose . In all groups treated with the substance, the death of animals was not recorded. In the group receiving the maximum dose, 1 animal died. Thus, according to the results of the study, we can say that the maximum tolerated dose is at least 5000 mg / kg, and the LD50 exceeds 5000 mg / kg (per os, mice, females).

Claims

Claim

The use of (18, ZaK, 4K, 7a8) -H- (2,2,4,7a-tetramethyl octahydro-1,4-ethanoinden-) -acetamide of formula I:

as an inhibitor of the reproduction of influenza virus.